Phaim is developing a novel therapeutic platform aimed at curing, improving, halting, or preventing autoimmune diseases, with its first application targeting Type 1 Diabetes. The approach seeks to create a new class of medicines that reset the immune system, and the pipeline also plans to address conditions such as psoriasis, rheumatoid arthritis, and multiple sclerosis.
Funding
Funding not disclosed
Founders
Product
Problem
Autoimmune diseases such as Type 1 Diabetes, multiple sclerosis, psoriasis, and rheumatoid arthritis currently have limited treatment options that only manage symptoms and do not cure, halt progression, or prevent disease onset. This leaves millions of patients dependent on lifelong therapy with significant health and economic burdens.
Solution
Phaim is creating a novel therapeutic platform that re‑programs the immune system to restore self‑tolerance, aiming to cure, improve, halt, or prevent autoimmune conditions. The first application targets Type 1 Diabetes, leveraging a new class of medicines designed to reset immune responses that attack pancreatic beta cells. By addressing the underlying immune dysfunction rather than merely managing symptoms, the platform seeks durable disease modification. The same technology is being extended to a pipeline that includes psoriasis, rheumatoid arthritis, and multiple sclerosis, covering a large portion of the autoimmune market. Phaim’s approach is intended to provide a one‑time or short‑course treatment that could eliminate the need for chronic immunosuppression.
Target Audience
Primary customers are pharmaceutical partners, biotech investors, and clinical research organizations seeking disease‑modifying therapies for autoimmune diseases, as well as healthcare systems aiming to reduce long‑term treatment costs.
Features
- Proprietary immune‑resetting drug class that induces durable self‑tolerance to autoantigens
- Platform architecture enables rapid adaptation of the core technology to multiple autoimmune indications
- Preclinical and early clinical programs focused on disease‑modifying outcomes rather than symptom control
- Scalable manufacturing process designed for biologics with consistent potency and safety profiles
- Integrated biomarker strategy to monitor immune re‑education and predict therapeutic success